Advertisement

Betarezeptorenblocker

  • Björn Lemmer

Zusammenfassung

Betarezeptorenblocker spielen eine wichtige Rolle bei der Behandlung kardiovaskulärer Erkrankungen. Hauptindikationen sind arterielle Hypertonie, koronare Herzkrankheit, tachykarde Herzrhythmusstörungen und chronische Herzinsuffizienz. Wichtigste Gruppe sind die β1-selektiven Betarezeptorenblocker.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Bristow MR (2000): β-Adrenergic receptor blockade in chronic heart failure. Circulation 101: 558–569.PubMedCrossRefGoogle Scholar
  2. Bowman AJ, Chen CP, Ford GA (1994): Nitric oxide mediated venodilator effects of nebivolol. Brit J Clin Pharmacol 38:199–204.CrossRefGoogle Scholar
  3. Brodde OE (1991): Beta 1-and beta 2-adrenoceptors in the human heart: properties, function, and alterations in chronic heart failure. Pharmacol Rev 43: 203–242.PubMedGoogle Scholar
  4. Chobanian AV, Bakris GL, Black HR, et al (2003): Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC7). Hypertension 42:1206–1252. http://www.nhlbi.nih.gov/guidelines/hypertension/.PubMedCrossRefGoogle Scholar
  5. CIBIS II Study (1999): The cardiac insufficiency bisoprolol study II (CIBIS II): a randomised trial. Lancet 353: 9–13.CrossRefGoogle Scholar
  6. Dargie HJ (2003): β-Blockers in heart failure. Lancet 362:2–3.PubMedCrossRefGoogle Scholar
  7. Deutsche Liga zur Bekämpfung des hohen Blutdrucks/Deutsche Hochdruckliga (2003): Leitlinien für die Prävention, Erkennung, Diagnostik und Therapie der arteriellen Hypertonie. http://www.paritaet.org/hochdruckliga/Leit2003.htm.Google Scholar
  8. Eschenhagen T (2004): Herzinsuffizienz. In: Lemmer B, Brune K (Hrsg): Pharmakotherapie — Klinische Pharmakologie, 12. Auflage, Springer, Heidelberg New York, S. 223–258.Google Scholar
  9. Frishman WH, Kostis J, Strom J, Hossler M, Ekayam U et al (1979): Clinical pharmacology of the new beta-adrenergic blocking drugs. Part 6: A comparison of pindolol and propranolol in the treatment of patients with angina pectoris. The role of intrinsic sympathomimetic activity. Am Heart J 98: 526–535.PubMedCrossRefGoogle Scholar
  10. Ijzerman AP, Soudijn W (1989): The antiarrhythmic properties of β-adrenoceptor antagonists. Trends Pharmacol Sci 10:31–36.PubMedCrossRefGoogle Scholar
  11. Kilbinger H, Rahn K-H (2004): Hypertonic In: Lemmer B, Brune K (Hrsg): Pharmakotherapie — Klinische Pharmakologie, 12. Auflage, Springer, Berlin Heidelberg New York, S. 209–226.Google Scholar
  12. Meier K, Lemmer B (2004): Blood pressure and heart rate after metoprolol or nebivolol and effects on nitric oxide urinary excretion in spontaneously hypertensive rats with and without 1-NAME. Z Kardiol/Germ J Cardiol 93(Suppl 3): P1320.Google Scholar
  13. MERIT-HF Study (1999): Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL randomised intervention trial in congestive heart failure. Lancet 353:2001–2007.CrossRefGoogle Scholar
  14. Packer M, Coats AJS, Fowler MB, Katus HA et al (2001): Effect of Carvedilol on survival in severe chronic heart failure. N Engl J Med 344:1651–1658.PubMedCrossRefGoogle Scholar
  15. Pesant Y, Marc-Aurele J, Bielmann P, Alaupovic P, Cartier P, Bichet D, et al (1999): Metabolic and antihypertensive effects of nebivolol and atenolol in normome-tabolic patients with mild-to-moderate hypertension. Am J Ther 6:137–147.PubMedCrossRefGoogle Scholar
  16. Poirier L, Cléroux J, Nadeau A, Lacourcière Y (2001): Effects of nebivolol and atenolol on insulin sensitivity and haemodynamics in hypertensive patients. J Hypertens 19:1429–1435.PubMedCrossRefGoogle Scholar
  17. Poole-Wilson PA, Svedberg K, Geland JGF, Lenarda A, Hanrath P, Komajda M et al (2003): Comparison of Carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 362: 7–13.PubMedCrossRefGoogle Scholar
  18. Poynard T, Calés P, Pasta L, Ideo G, Pascal J-P et al and the Franco-Italian Multi-center Study Group (1991): Beta-adrenergic-antagonist drugs in the prevention of gastrointestinal bleeding in patients with cirrhosis and esophageal varices. N Engl J Med 324:1532–1538.PubMedCrossRefGoogle Scholar
  19. Quyyumi AA, Wright C, Mockus L, Fox KM (1984): Effect of partial agonist activity in β-blockers in severe angina pectoris: A double blind comparison of pindolol and atenolol. Brit Med J 289: 951–953.CrossRefGoogle Scholar
  20. Ruf G, Trenk D, Jahnchen E, Roskamm H (1994): Determination of the anti-ischemic activity of nebivolol in comparison with atenolol. Int J Cardiol 43: 279–285.PubMedCrossRefGoogle Scholar
  21. Schrör K, Kelm M (2004): Koronare Herzkrankheit. In: Lemmer B, Brune K (Hrsg): Pharmakotherapie — Klinische Pharmakologie, 12. Auflage, Springer Verlag, Berlin Heidelberg New York, S. 259–275.Google Scholar
  22. Tzemos N, Lim PO, MacDonald TM (2001): Nebivolol reverses endothelial dysfunction in essential hypertension: a randomised, double-blind, crossover study. Circulation 104: 511–514.PubMedCrossRefGoogle Scholar
  23. Van Nueten L, Taylor FR, Robertson JI (1998): Nebivolol vs atenolol and placebo in essential hypertension: a double-blind randomised trial. J Hum Hypertens 12: 135–140.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2004

Authors and Affiliations

  • Björn Lemmer
    • 1
  1. 1.Institut für Pharmakologie und ToxikologieFakultät für Klinische Medizin Mannheim der Universität HeidelbergMannheim

Personalised recommendations